Skip to main content

SiriusPoint Completes Sale of ArmadaCare to Ambac

Tipranks - Tue Nov 4, 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

SiriusPoint ( (SPNT) ) has issued an announcement.

On October 31, 2025, SiriusPoint Ltd. completed the sale of its wholly owned supplemental health insurance program manager, ArmadaCare, to Ambac Financial Group Inc. for $250 million. This transaction, initially announced on September 29, 2025, marks a strategic move for SiriusPoint, potentially impacting its market positioning and operational focus.

The most recent analyst rating on (SPNT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on SiriusPoint stock, see the SPNT Stock Forecast page.

Spark’s Take on SPNT Stock

According to Spark, TipRanks’ AI Analyst, SPNT is a Neutral.

SiriusPoint’s overall stock score is driven by a positive earnings call and stable financial position, despite mixed financial performance and neutral technical indicators. The company’s strong return on equity and premium growth are significant positives, while cash flow challenges and valuation concerns temper the outlook.

To see Spark’s full report on SPNT stock, click here.

More about SiriusPoint

SiriusPoint Ltd. operates in the insurance and reinsurance industry, focusing on providing a range of insurance products and services.

Average Trading Volume: 843,267

Technical Sentiment Signal: Buy

Current Market Cap: $2.13B

For detailed information about SPNT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.